Trial · NCT01751802
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Behavior Problems Inventory - Self-Injurious Behavior Subscale | Subject #1: Ecopipam Then Placebo Then Ecopipam | BPI Self-Injurious Behavior Subscale, Baseline | 26 | scores on a scale | |
| Behavior Problems Inventory - Self-Injurious Behavior Subscale | Subject #2: Ecopipam Then Placebo Then Ecopipam | BPI Self-Injurious Behavior Subscale, Baseline | 10 | scores on a scale | |
| Behavior Problems Inventory - Self-Injurious Behavior Subscale | Subject #3: Placebo Then Ecopipam Then Placebo | BPI Self-Injurious Behavior Subscale, Baseline | 78 | scores on a scale | |
| Behavior Problems Inventory - Self-Injurious Behavior Subscale | Subject #4: Placebo Then Ecopipam Then Placebo | BPI Self-Injurious Behavior Subscale, Baseline | 27 | scores on a scale | |
| Behavior Problems Inventory - Self-Injurious Behavior Subscale | Subject #1: Ecopipam Then Placebo Then Ecopipam | BPI Self-Injurious Behavior Subscale, 6 weeks | 24.1 | scores on a scale | |
| Behavior Problems Inventory - Self-Injurious Behavior Subscale | Subject #2: Ecopipam Then Placebo Then Ecopipam | BPI Self-Injurious Behavior Subscale, 6 weeks | 4.3 | scores on a scale | |
| Behavior Problems Inventory - Self-Injurious Behavior Subscale | Subject #3: Placebo Then Ecopipam Then Placebo | BPI Self-Injurious Behavior Subscale, 6 weeks | 58.3 | scores on a scale | |
| Behavior Problems Inventory - Self-Injurious Behavior Subscale | Subject #4: Placebo Then Ecopipam Then Placebo | BPI Self-Injurious Behavior Subscale, 6 weeks | 22.6 | scores on a scale | |
| Behavior Problems Inventory - Self-Injurious Behavior Subscale | Subject #1: Ecopipam Then Placebo Then Ecopipam | BPI Self-Injurious Behavior Subscale, 12 weeks | 25.2 | scores on a scale | |
| Behavior Problems Inventory - Self-Injurious Behavior Subscale | Subject #2: Ecopipam Then Placebo Then Ecopipam | BPI Self-Injurious Behavior Subscale, 12 weeks | 11.6 | scores on a scale | |
| Behavior Problems Inventory - Self-Injurious Behavior Subscale | Subject #3: Placebo Then Ecopipam Then Placebo | BPI Self-Injurious Behavior Subscale, 12 weeks | 21.5 | scores on a scale | |
| Behavior Problems Inventory - Self-Injurious Behavior Subscale | Subject #4: Placebo Then Ecopipam Then Placebo | BPI Self-Injurious Behavior Subscale, 12 weeks | 16.0 | scores on a scale | |
| Behavior Problems Inventory - Self-Injurious Behavior Subscale | Subject #1: Ecopipam Then Placebo Then Ecopipam | BPI Self-Injurious Behavior Subscale, 18 weeks | 21 | scores on a scale | |
| Behavior Problems Inventory - Self-Injurious Behavior Subscale | Subject #2: Ecopipam Then Placebo Then Ecopipam | BPI Self-Injurious Behavior Subscale, 18 weeks | 6.6 | scores on a scale | |
| Behavior Problems Inventory - Self-Injurious Behavior Subscale | Subject #3: Placebo Then Ecopipam Then Placebo | BPI Self-Injurious Behavior Subscale, 18 weeks | 28.7 | scores on a scale | |
| Behavior Problems Inventory - Self-Injurious Behavior Subscale | Subject #4: Placebo Then Ecopipam Then Placebo | BPI Self-Injurious Behavior Subscale, 18 weeks | NA | scores on a scale | |
| Safety Summary of Ecopipam in Patients With Lesch-Nyhan Disease: Total Number of Serious and Non-Serious Adverse Events Experienced During 3 Double-blind Crossover Periods | Ecopipam | Non-Serious | 42 | adverse events | |
| Safety Summary of Ecopipam in Patients With Lesch-Nyhan Disease: Total Number of Serious and Non-Serious Adverse Events Experienced During 3 Double-blind Crossover Periods | Placebo | Non-Serious | 7 | adverse events | |
| Safety Summary of Ecopipam in Patients With Lesch-Nyhan Disease: Total Number of Serious and Non-Serious Adverse Events Experienced During 3 Double-blind Crossover Periods | Ecopipam | Serious | 2 | adverse events | |
| Safety Summary of Ecopipam in Patients With Lesch-Nyhan Disease: Total Number of Serious and Non-Serious Adverse Events Experienced During 3 Double-blind Crossover Periods | Placebo | Serious | 1 | adverse events |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01751802/results